ストックスクリーナーアプリを入手
2.62
0.76%
-0.02
アフターアワーズ：
2.62
Altimmune Inc (ALT) 最新ニュース
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Altimmune sets pemvidutide's phase 3 MASH playbook as AUD data near - MSN
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
Why is Altimmune (ALT) down 11.3% since last earnings report? - MSN
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Yahoo Finance
Altimmune touts pemvidutide momentum ahead of phase 3 MASH trial - MSN
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Here's why you should add Altimmune stock to your portfolio now - MSN
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Yahoo Finance
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
Altimmune Shares Drop After $225 Million Offering Prices - Moomoo
ALT and the Rise of Dual Agonists Targeting Liver Disease - Yahoo Finance
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup - Yahoo Finance
Is Altimmune Worth Buying Ahead of 2026 Catalysts? - Yahoo Finance
Altimmune (ALT) Gains Ground Amid Positive Momentum, Testing Key Resistance LevelsHedge Fund Exposure - newsline.com
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial - Barchart.com
Altimmune director Gill buys $31k in company stock - Investing.com
ALT: Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - TMX Newsfile
Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com
Citizens reiterates Altimmune stock rating on fibrosis trial data By Investing.com - Investing.com Canada
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune (MEX:ALT1) Other Liabilities for Banks - GuruFocus
Altimmune Inc (ALT) Stock Price, Quote, News & History - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Altimmune reports 48-week pemvidutide trial results at EASL By Investing.com - Investing.com Australia
Altimmune reports 48-week pemvidutide trial results at EASL - Investing.com UK
Liver disease trial: pemvidutide lowers fats, weight and blood pressure - Stock Titan
Altimmune's Q1 loss narrower than expected, revenues nil - MSN
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease - Moomoo
Altimmune to Participate in Upcoming Investor Conferences - The Manila Times
Altimmune, Inc. to Participate in Upcoming Investor Conferences in June 2026 - Quiver Quantitative
Altimmune reports positive pemvidutide trial data for MASH By Investing.com - Investing.com Nigeria
Altimmune reports positive pemvidutide trial data for MASH - Investing.com
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):